Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
Business Wire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 sales $283.7 million, up 14% year over year
- ➤Adjusted EBITDA $18.0 million, versus $2.8 million in Q3 2025
- ➤Operating loss narrowed to $2.4 million from $22.9 million
- ➤2026 sales guidance reaffirmed at approximately $1.065 billion to $1.085 billion
- ➤Pharmacy channel reached 15% of U.S. sales through pay-as-you-go reimbursement
Expert Statements
John Sheridan, President and Chief Executive Officer of Tandem Diabetes Care
“Tandem’s third-quarter performance demonstrates that our strategy is delivering results”
John Sheridan, President and Chief Executive Officer of Tandem Diabetes Care
“We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.”
Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.